Bone infections caused by Acremonium species are uncommon, and, to our knowledge, there have been no reports of sequential acremoneium bone infections at two distant sites. We describe a patient who had previously undergone splenectomy who spontaneously developed acremonium endophthalmitis followed by diskitis of the lumbar spine.
both drugs were discontinued because of the results of antifungal susceptibility tests; the tests indicated that the isolate was resistant to amphotericin B and fluconazole but susceptible to ketoconazole, miconazole, itraconazole, and saperconazole.
He was given oral itraconazole (200 mg twice daily) for 45 weeks (until 30 June 1994). His back pain slowly abated, and by early March 1994 the erythrocyte sedimentation rate had normalized. In November 1994, another MRI showed no evidence of diskitis. The patient remains well 18 months after treatment with antifungal agents was discontinued.
A. falciforme causes -80% of acremonium infections in humans [1] . Our report is unique in that the acremonium infection involved two distant sites in the patient's body, the eye and the disk space. The only preceding trauma was the right carotid endarterectomy performed 9 days before his symptoms began. Since no other cases of acremonium infection have been reported locally, we cannot suggest an environmental source [2] .
Although Acremonium species often infect the eye, infection of bone, other than that secondary to mycetoma in the tropics, is rare in the United States [1, 3] ; only one patient with acremonium osteomyelitis of the calvarium [4] and two patients with septic arthritis of the knee [5, 6] have been described.
Oral itraconazole was successfully used to treat two patients with A. falciforme infection; one had mycetoma of the face [7] , and the other was an infant with severe combined immunodeficiency disease [8] .
The appropriate therapy for acremonium infections is unknown. The results of treatment of acremonium endophthalmitis have generally been poor [9] . Many Acremonium isolates are resistant to amphotericin B, ketoconazole, and itraconazole [10] . However, ketoconazole, was successfully used to treat mycetomas in Madras, India [3] . Itraconazole may prove useful for treating acremonium infections if in vitro susceptibility is proven.
Successful Treatment of Stomatococcus mucilaginosus Meningitis with Intravenous Vancomycin and Intravenous Ceftriaxone
Stomatococcus mucilaginosus is a gram-positive bacterium normally found in the oropharynx and upper respiratory tract [1] [2] [3] . S. mucilaginosus has been reported to cause bacteremia, intravascular catheter infections, endocarditis, peritonitis, respiratory infections, and intracranial infections [3] . Five detailed reports of S. mucilaginosus meningitis in immunocompromised hosts have been published [2] [3] [4] [5] [6] . The one patient who survived longer than the period of acute treatment received intrathecal vancomycin and intravenous antibiotics; thus, the recommendation was made that intrathecal vancomycin be administered to patients with meningitis due to S. mucilaginosus. We describe a case of S. mucilaginosus meningitis in a child with leukemia in whom infection resolved without the use of intrathecal vancomycin therapy.
A 5-year-old child with relapsed acute lymphoblastic leukemia developed chemotherapy-induced neutropenia; three of five blood cultures yielded S. mucilaginosus, and four of five blood cultures yielded Streptococcus mitis. CSF obtained by lumbar puncture and a transthoracic echocardiogram did not show any abnormalities. The patient received a 7-day course of vancomycin and a 17-day course of ceftazidime through a Hickman catheter before his parents requested that chemotherapy and antibiotic therapy be discontinued.
The patient's neutropenia resolved; he became afebrile and remained clinically stable until 6 weeks later when he awoke with a stiff neck. He had no fever, chills, nausea, sore throat, or chest pain. Findings on physical examination were unremarkable. His peripheral WBC count was 20,300/mm3 with 76% polymorphonuclear leukocytes, 4% lymphocytes, 4% monocytes, and 7% blast cells. Laboratory studies of the CSF revealed the following values: WBC count, 1,130/mm3 with 88% polymorphonuclear leukocytes and 10% lymphocytes; RBC count, 10/mm3; glucose, 43 mg/dL; and protein, 124 mg/dL. Gram-stained smears of CSF revealed sheets of polymorphonuclear leukocytes with occasional intracellular gram-positive cocci. Findings on a chest radiograph and a head CT scan were normal.
Treatment with intravenous ceftriaxone (500 mg b.i.d.) and ampicillin (1 g q6h) was administered immediately. The patient became febrile and lethargic the next day, and intravenous vancomycin (240 mg q8h) was added to the regimen; treatment with 
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ampicillin was discontinued when cultures of CSF yielded only S. mucilaginosus. The electrophoretic patterns determined by use of the restriction enzyme HindIII indicated that the blood and CSF isolates were identical (data not shown).
Over the next 24 hours, the patient's condition markedly improved, and he became afebrile and alert. Cultures of both blood samples drawn before antibiotic therapy was started remained negative. Repeated cultures of CSF obtained on hospital day 13 were sterile, and the pleocytosis had almost completely resolved.
S. mucilaginosus is reportedly susceptible to vancomycin, ampicillin, cefotaxime, imipenem, and rifampin [7] and not reliably susceptible to penicillin, clindamycin, or oxacillin [1, [5] [6] [7] [8] . Intrathecal vancomycin, when administered as an adjunct to intravenous antibiotics, eradicated S. mucilaginosus from the CSF in two cases [2, 4] ; however, one of the patients subsequently had a seizure and died 2 weeks later [4] . Because the other patient survived, it was recommended that intrathecal vancomycin be given to patients with meningitis due to S. mucilaginosus. In our patient's case, S. mucilaginosus was successfully eradicated from the CSF after treatment with intravenous vancomycin and intravenous ceftriaxone was given for 21 days.
